期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 13, 期 12, 页码 1631-1640出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.13.12.1631
关键词
atrasentan; endothelin 1; endothelin receptor A; prostate cancer
Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cellular events such as proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and the alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biological and clinical activity in patients with prostate cancer has been demonstrated in a Phase III clinical setting by the suppression of markers of biochemical and clinical prostate cancer progression, and by a delay in time to disease progression, especially in patients with bone disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据